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ABSTRACT
Idiosyncratic drug-induced liver injury (DILI), when severe, can be associated with significant morbidity and mortality. Currently,
there are no specific therapies for DILI, apart from corticosteroids for drug-induced autoimmune hepatitis caused by drugs such as
nitrofurantoin orminocycline.We present 2 cases of DILI that improvedwith corticosteroid therapy despite the lack of autoimmune
features by serology or histology. The current observationsmake a strong case for formally testing corticosteroids in a controlled trial
in patients with suspected DILI.
INTRODUCTION
Corticosteroid use is common in patients with idiosyncratic drug-induced liver injury (DILI).1 Although the mainstay of idio-
syncratic DILI therapy is the withdrawal of the offending agent, the use of ursodiol and steroids may be justified in instances where
DILI cannot be distinguished from autoimmune hepatitis or when it presents with an autoimmune phenotype because of medi-
cations such as nitrofurantoin or minocycline. We present 2 well-characterized cases of DILI without autoimmune features and yet
responding rapidly to corticosteroids, making a case for further investigating their use as a treatment option.
CASE REPORT
Patient 1: A 61-year-old woman with small bowel gastrointestinal stromal tumor was started on imatinib 400 mg a day. Ap-
proximately 3 months after initiation of imatinib, she had a marked increase in the liver enzymes to alanine transferase (ALT)
758 U/L, aspartate transferase 354 U/L, and total bilirubin of 0.8 mg/dL, with normal alkaline phosphatase. The patient also became
symptomatic with abdominal distention and pedal edema. Imatinib was discontinued. Thorough workup excluded competing
etiologies with negative viral hepatitis B and C antibodies and autoimmune hepatitis panel, including antismooth muscle antibody
and anti-LKM1.A liver biopsy showedwidespread perivenulitis with extensive zone 3 necrosis including bridging necrosis. Amild to
moderate portal inflammatory infiltrate of lymphocytes was present with intermingled eosinophils and neutrophils. Interface
hepatitis was only mild and not indicative of autoimmune hepatitis. Bile ducts were present in all portal tracts with only mild
epithelial damage (Figure 1).
After a brief downward trend, the liver enzymes increased to a peak ALT of 1184 U/L, aspartate transferase of 693 U/L, and total
bilirubin of 1.7mg/dL. The patientwas empirically initiated on oral budesonide (9mg/d)with a slow taper. This treatment resulted in
an immediate decline in enzymes and symptomatic improvement. Because of zone 3 necrosis and suspected dose-related toxicity, we
tested for drug-metabolizing enzyme polymorphisms and found her to be a cytochrome P450 3A5 poormetabolizer. After 3months
of treatment and complete normalization of liver enzymes, she was rechallengedwith imatinib at 200mg every other daywith careful
monitoring while she remained on 3 mg of budesonide. However, her liver enzymes rapidly increased, prompting permanent
discontinuation of imatinib (Figure 1). The dosage of budesonide was increased to 9 mg/d, with rapid improvement in her liver
enzymes. At her most recent visit, her liver enzymes were normal and her budesonide was completely discontinued after the
prolonged taper.
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Patient 2: A 61-year-old woman with breast cancer was pre-
scribed a 10-day course of cephalexin (500 mg twice daily
orally) after tumor resection. Two weeks later, she had a repeat
course of cephalexin at a similar dosage and duration for cel-
lulitis after port placement for chemotherapy. Approximately 1
month later, she developed nonspecific symptoms including
fatigue and syncope. Blood work revealed cholestatic pattern
elevation in liver enzymes with a total bilirubin of 10.4 mg/dL,
ALT of 129 U/L, and alkaline phosphatase of 587 U/L with
a corresponding R-factor of 0.7. Serologic workup excluded
acute viral and autoimmune hepatitis. Liver ultrasound
revealed no biliary dilation. A liver biopsy showed chole-
static hepatitis with mild portal inflammatory infiltrate
of lymphocytes and eosinophils. There was no interface
Figure 1. (A) Liver test trends in relation to exposure to the implicated drug (imatinib) and initiation of steroid. The rechallenge with imatinib
was associated with a repeat increase in alanine aminotransferase and total bilirubin levels. (B) Perivenulitis with necrosis and an in-
flammatory infiltrate of lymphocytes and pigmented macrophages (hematoxylin and eosin [H&E] 103). (C) Moderate portal inflammation
consisting mainly of lymphocytes with a few intermingled eosinophils. Mild interface hepatitis, not indicative of autoimmune hepatitis, is
present. Bile ducts are present and show minimal epithelial damage (H&E 1003). ALT, alanine transferase; ALP, alkaline phosphatase.
Figure 2. (A) Liver test trends in relation to exposure to cephalexin and initiation of budesonide 142 days after the onset of liver injury. The
timing of the liver biopsy indicated on the x axis. (B) Portal tract with mild inflammatory infiltrate of lymphocytes and eosinophils with marked
biliary epithelial damage. There is no interface hepatitis (hematoxylin and eosin [H&E] 103). (C) Portal tract with no inflammation. Bile ducts
are present (H&E 1003). ALT, alanine transferase; ALP, alkaline phosphatase.
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hepatitis. Foci of inflammation and clusters of foamy mac-
rophages were scattered throughout the lobules. Bile ducts
were present in all portal tracts, but there was marked bile
duct damage with flattening of the epithelium and nuclear
overlapping and loss. Bile plugs were present within the
canaliculi. Although the total bilirubin improved, her liver
enzymes remained elevated, prompting a referral to our
institution. The follow-up biopsy showed minimal ductular
proliferation without inflammation, bile duct damage, or
bile duct loss (Figure 2).
Despite convincing evidence for DILI based on temporal as-
sociation, liver histology, and adequate exclusion of competing
etiology, persistent liver test abnormalities after attempted
rechallenge prompted us to start budesonide at 9 mg per day
and ursodiol at 600 mg per day 142 days after DILI onset. The
patient responded with dramatic symptom improvement and
liver test normalization in a 2weeks’ span. Continued treatment
with prolonged steroid taper after 3 months at maintained
initial dose resulted in further improvement.
DISCUSSION
For both suspected DILI cases presented here, we excluded
competing etiologies, including autoimmune hepatitis. In both
instances, the patients were under the care of oncologists who
could not initiate (patient 1) or resume (patient 2) chemo-
therapy until normalization of the liver test was achieved. Be-
cause these tests remained persistently elevated, the clinicians
reported to a trial of empiric budesonide, which resulted in
a dramatic improvement in liver tests. Corticosteroid treatment
of DILI is not a standard of treatment but has been well docu-
mented. In a review of patients who received this treatment in
the DILI Network prospective study, patients were younger,
largely women, andwithmore severe serological derangements.
It was also noted that this group demonstrated a higher
mortality rate, possibly attributable to the fact that these
patients suffered from worse liver injury before treatment.1
Relatively widespread empiric use of corticosteroids in DILI
and our current observations make a strong case for more
formal investigations into its efficacy as a treatment in patients
with suspected DILI.
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